看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
2 I, P) Q% p1 V2 _4 A. F: u4 p; I0 e4 G1 ~$ |; v' e8 X6 b
) e2 Q4 p* p( |5 F+ a( A* l
Currently available feasibility data for possible combination strategies.
, v1 u& _" G7 V3 H# B! @* Q8 p+ s————————————————————————————————
# i8 _* d1 |9 a/ U+ e8 [3 ZCombination Feasibility according to preliminary data / b* @7 B) t7 K7 `
——————————————————————————————————
9 \. [. N4 ?6 hBevacizumab + sorafenib Yes, reduced dose / ~3 y! g) c. m% ?4 F W
Bevacizumab + sunitinib† No 1 K- l( }* p2 c
Bevacizumab + temsirolimus Yes
4 t% h1 ]) V1 h3 {: l& ?4 pBevacizumab + everolimus Yes
% r& L) W; l; U3 O6 K' t% fSorafenib + sunitinib ? . J' L4 H9 j2 i. O [1 |$ X
Sorafenib + temsirolimus Yes, reduced dose 0 S J3 {# f- s: Q- u
Sorafenib + everolimus Yes, reduced dose 3 W8 ]0 w1 n% S# s" M4 c
Sunitinib + temsirolimus† No
$ q- m1 x! E/ h! j) CSunitinib + everolimus ? + ]9 l- v% U2 _" G+ I( J
Temsirolimus + everolimus ?
! |, B7 w" w5 g- {) d, x————————————————————
* H. U# ^$ ?& P! K†Led to US FDA warning.$ h2 m* ~ f9 G3 i* h
?: As yet unattempted combination.
- u" `- P# W8 P& v |